Topics to include DNA and RNA profiling and next-generation
sequencing of tumors
SAN ANTONIO--(BUSINESS WIRE)--Dec. 3, 2018--
Significant developments in breast cancer research will be presented by
NantHealth (NASDAQ: NH) at the San Antonio Breast Cancer Symposium this
week. NantHealth, a leader in breakthrough cancer research and solutions
to improve patient care and lower healthcare costs, will discuss the
findings of three investigations, which examine the theme of providing
oncologists with insights that enable cancer treatment tailored to the
individual characteristics of each patient.
The Symposium, which will be held at the Henry B. Gonzalez Convention
Center in San Antonio from Dec. 4-8, is designed to provide
state-of-the-art information on the experimental biology, etiology,
prevention, diagnosis and therapy of breast cancer and premalignant
breast disease, to an international audience of academic and private
physicians and researchers.
“About 1 in 8 U.S. women or about 12.4% will develop invasive breast
cancer over the course of her lifetime. Such staggering statistics make
breast cancer research and progress critical,” said Sandeep “Bobby”
Reddy MD, Chief Medical Officer, NantHealth. “We are honored to have an
integral role at the San Antonio Breast Cancer Symposium, which provides
a dynamic forum for interaction, communication, and education for a
broad spectrum of researchers, health professionals, and those with a
special interest in breast cancer.”
Title: “Germline potentially pathogenic variants in breast cancer
intrinsic molecular subtypes are not associated with somatic TMB”
Author: Elias Obeid, MD, MPH
Senior Author: Christopher
Contributors: Sandeep “Bobby” Reddy MD; Lori J.
Goldstein, MD; Mary B. Daly, MD, PhD; Stephen C. Benz, PhD; and Michael
J. Hall, MD, MS
Description: Comprehensive DNA and RNA
profiling of 270 patients revealed intrinsic molecular subtypes of
breast cancer have significantly distinct profiles of pathogenic
germline variants. However, despite some breast cancer subtypes having
higher frequency of germline pathogenic variants within DNA-damage
repair genes, there is little evidence that these patients have
subsequently higher mutational burden within their somatic genomes.
Takeaway: Pathogenic germline variants in key DNA damage repair
genes such as BRCA1/2 are likely not adequate biomarkers for immune
checkpoint therapy response, but are potentially biomarkers of
differential tumorigenesis pathways.
Title: “Time-course DNA and RNA profiling of tumors from
intra-patient cross-over trial of sequential use of aromatase inhibitors”
Author: Charles Vaske
Senior Authors: Vessela Kristensen
and Jürgen Geisler
Contributors: Rahul Parulkar, Nazli
Bahrami, Torill Sauer, Marie Loeng, Berit Gravdehaug, Belal Aljabri,
Vahid Bemanian, Jonas Lindstrøm and Torben Lüders
Early analysis from the ongoing NEOLETEXE trial examines a time-series
of biopsies taken while transitioning patients from steroidal to
non-steroidal aromatase inhibitors (AI) and vice versa. Acquired markers
of AI-therapy resistance, and potential markers of sequential therapy
sensitization, were explored. Two months after initial therapy,
mutational burden decreased and clonality increased, yet by 4mo
post-initialization mutations particularly in PIK3CA had repopulated.
Takeaway: Switching AI therapies sequentially in a clinical study is
a model system to study differences in anti-tumor-effects of AIs. This
ongoing trial may lead to a novel strategy to resensitize tumors to
hormonal treatment and to elucidate the differences between steroidal
and non-steroidal AIs.
Title: “Identification of a neoantigen targeted by
tumor-infiltrating lymphocytes in a patient with Her2+ breast cancer”
Author: Hannah Kranich
Senior Authors: Peter A. Fasching
and Anita N. Kremer
Contributors: Andrew Nguyen, Hanna
Hübner, Erber Ramona, Judith Bausenwein, Edith D. van der Meijden,
Michael P. Lux, Sebastian Jud, Claudia Rauh, John Zachary Sanborn,
Stephen C. Benz, Shahrooz Rabizadeh, Matthias W. Beckmann, Andreas
Mackensen and Matthias Rübner
Description: In our study, we
identify tumor infiltrating T-cells (TILS) that recognize tumor specific
mutations (Neoepitopes) found by next-generation sequencing of breast
cancer tumors. These identified TILS are further immortalized and
characterized to bind the patient’s specific HLA alleles.
Takeaway: Identification of TILS recognizing patient specific
neoepitopes allow development of personalized medicine in a pre-clinical
Since 1977, the San Antonio Breast Cancer Symposium mission has been to
provide state-of-the-art information on breast cancer research. From a
one-day regional conference, the Symposium has grown to a five-day
program attended by a broad international audience of academic and
private researchers and physicians from over 90 countries. For more
information visit: https://www.sabcs.org/2018-SABCS-sup-sup.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, uses
personalized data to improve patient care and lower healthcare costs.
NantHealth leads the way in providing oncologists with insights that
enable cancer treatment tailored to the individual characteristics of
each patient. NantHealth solutions reduce the cost of care by connecting
patient data and streamlining the accurate collection and sharing of
that data--starting from a patient’s bedside, extending to payers and
providers. NantHealth improves clinical decision support, eliminates
unwarranted care and seeks to enhance. For more information please visit www.nanthealth.com.
NantOmics, a member of the NantWorks ecosystem of companies, delivers
molecular analysis capabilities with the intent of providing actionable
intelligence and molecularly driven decision support for cancer patients
and their providers at the point of care. NantOmics is the first
molecular analysis company to pioneer an integrated approach to
unearthing the genomic variants and transcriptomic changes that initiate
and drive cancer, by analyzing both normal and tumor cells from the same
patient and connecting drugs to DNA to RNA changes in the tumor.
NantOmics has a highly scalable cloud-based infrastructure capable of
storing and processing thousands of genomes a day. For more information
please visit www.nantomics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181203005184/en/